Dynavax (DVAX) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Dynavax Announces Fourth Quarter and Full Year 2018 Financial Results
February 26, 2019 4:05 PM ESTFourth quarter 2018 HEPLISAV-B® net product revenue of $3.9 millionPhase Ib/2 safety data for inhaled DV281 will be presented at the AACR Annual MeetingSD-101 demonstrates consistent and meaningful clinical benefit to anti-PD-1 therapyConference call to be held today at 4:30 p.m. ET/1:30 p.m. PT
BERKELEY, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2018. Â
I am proud of our 2018 achievements,... More
